Design and Characterization of Glyceryl Monooleate-Nanostructures Containing Doxorubicin Hydrochloride

被引:38
作者
Gagliardi, Agnese [1 ]
Cosco, Donato [2 ]
Udongo, Betty P. [3 ]
Dini, Luciana [4 ]
Viglietto, Giuseppe [1 ]
Paolino, Donatella [1 ]
机构
[1] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Campus Univ S Venuta, I-88100 Catanzaro, Italy
[2] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Campus Univ S Venuta, I-88100 Catanzaro, Italy
[3] Pincer Training & Res Inst, Plot 1127,Lukuli Zone 5, Kampala 500256, Uganda
[4] Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, I-00185 Rome, Italy
关键词
glyceryl monooleate; nanostructures; doxorubicin hydrochloride; poloxamers; polisorbates; multidrug resistance; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; DELIVERY; CARDIOTOXICITY; NANOPARTICLES; PHASES; SYSTEM; CANCER;
D O I
10.3390/pharmaceutics12111017
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Glyceryl monooleate (GMO) is one of the most popular amphiphilic lipids, which, in the presence of different amounts of water and a proper amount of stabilizer, can promote the development of well defined, thermodynamically stable nanostructures, called lyotropic liquid crystal dispersions. The aim of this study is based on the design, characterization, and evaluation of the cytotoxicity of lyotropic liquid crystal nanostructures containing a model anticancer drug such as doxorubicin hydrochloride. The drug is efficiently retained by the GMO nanosystems by a remote loading approach. The nanostructures prepared with different non-ionic surfactants (poloxamers and polysorbates) are characterized by different physico-chemical features as a function of several parameters, i.e., serum stability, temperature, and different pH values, as well as the amount of cryoprotectants used to obtain suitable freeze-dried systems. The nanostructures prepared with poloxamer 407 used as a stabilizer show an increased toxicity of the entrapped drug on breast cancer cell lines (MCF-7 and MDA-MB-231) due to their ability to sensitize multidrug-resistant (MDR) tumor cells through the inhibition of specific drug efflux transporters. Moreover, the interaction between the nanostructures and the cells occurs after just a few hours, evidencing a huge cellular uptake of the nanosystems.
引用
收藏
页码:1 / 20
页数:20
相关论文
共 48 条
[1]   Phytantriol based smart nano-carriers for drug delivery applications [J].
Akbar, Samina ;
Anwar, Aneela ;
Ayish, Abdullah ;
Elliott, Joanne M. ;
Squires, Adam M. .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 101 :31-42
[2]   Pluronics and MDR Reversal: An Update [J].
Alakhova, Daria Y. ;
Kabanov, Alexander V. .
MOLECULAR PHARMACEUTICS, 2014, 11 (08) :2566-2578
[3]   PEO-PPO Block Copolymers for Passive Micellar Targeting and Overcoming Multidrug Resistance in Cancer Therapy [J].
Alvarez-Lorenzo, C. ;
Sosnik, A. ;
Concheiro, A. .
CURRENT DRUG TARGETS, 2011, 12 (08) :1112-1130
[4]   Hexosome and hexagonal phases mediated by hydration and polymeric stabilizer [J].
Amar-Yuli, Idit ;
Wachtel, Ellen ;
Ben Shoshan, Einav ;
Danino, Dganit ;
Aserin, Abraham ;
Garti, Nissim .
LANGMUIR, 2007, 23 (07) :3637-3645
[5]   Increased Expression of P-Glycoprotein and Doxorubicin Chemoresistance of Metastatic Breast Cancer Is Regulated by miR-298 [J].
Bao, Lili ;
Hazari, Sidhartha ;
Mehra, Smriti ;
Kaushal, Deepak ;
Moroz, Krzysztof ;
Dash, Srikanta .
AMERICAN JOURNAL OF PATHOLOGY, 2012, 180 (06) :2490-2503
[6]   Doxil® - The first FDA-approved nano-drug: Lessons learned [J].
Barenholz, Yechezkel .
JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134
[7]   Cubosomes: The Next Generation of Smart Lipid Nanoparticles? [J].
Barriga, Hanna M. G. ;
Holme, Margaret N. ;
Stevens, Molly M. .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2019, 58 (10) :2958-2978
[8]  
Batrakova EV, 2001, J PHARMACOL EXP THER, V299, P483
[9]   DLS and zeta potential - What they are and what they are not? [J].
Bhattacharjee, Sourav .
JOURNAL OF CONTROLLED RELEASE, 2016, 235 :337-351
[10]   Interaction of dispersed cubic phases with blood components [J].
Bode, J. C. ;
Kuntsche, J. ;
Funari, S. S. ;
Bunjes, H. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 448 (01) :87-95